Table 2 Association between MEG3 rs10132552 and clinic-pathological parameters of breast cancer patients
From: Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer
| Â | rs10132552 n(%) | P value | |||||
|---|---|---|---|---|---|---|---|
TT | TC | CC | Dominant | Recessive | co-dominant | Additive | |
T stage | |||||||
 1~2 | 34(44.7) | 27(47.4) | 7(87.5) | 0.37 | 0.022* | 0.867 | 0.07 |
 3~4 | 42(55.3) | 30(52.6) | 1(12.5) | ||||
Lymph node status | |||||||
 Negative | 8(11) | 10(18.2) | 2(25) | 0.184 | 0.397 | 0.346 | 0.364 |
 Positive | 65(89) | 45(81.8) | 6(75) | ||||
ER | |||||||
 Negative | 22(28.2) | 18(31) | 2(25) | 0.783 | 0.79 | 0.686 | 0.905 |
 Positive | 56(71.8) | 40(69) | 6(75) | ||||
PR | |||||||
 Negative | 15(19.2) | 14(24.1) | 1(12.5) | 0.607 | 0.55 | 0.423 | 0.656 |
 Positive | 63(80.8) | 44(75.9) | 7(87.5) | ||||
HER2 | |||||||
 Negative | 54(69.2) | 34(58.6) | 4(50) | 0.147 | 0.4 | 0.28 | 0.312 |
 Positive | 24(30.8) | 24(41.4) | 4(50) | ||||
Ki67 | |||||||
 Low expression | 21(28.4) | 8(14.8) | 4(50) | 0.221 | 0.08 | 0.037* | 0.045* |
 High expression | 53(71.6) | 46(85.2) | 4(50) | ||||
Menopausal status | |||||||
 Premenopausal | 35(44.9) | 25(43.1) | 2(25) | 0.632 | 0.289 | 0.992 | 0.557 |
 Postmenopausal | 43(55.1) | 33(56.9) | 6(75) | ||||